Literature DB >> 7978074

Gamma/delta T-cell lymphoma involving the subcutaneous tissue and associated with a hemophagocytic syndrome.

I Avinoach1, S Halevy, S Argov, M Sacks.   

Abstract

A case of gamma/delta-positive T-cell lymphoma localized primarily in the subcutaneous adipose tissue and associated with an extensive hemophagocytic syndrome and a rapid, fatal outcome is presented. Previous reports of gamma/delta cutaneous and subcutaneous T-cell lymphomas are reviewed. To define the characteristics of a T-cell subset of neoplastic cells bearing the gamma/delta receptor in a subcutaneous lymphoma, we undertook clinical and laboratory examinations, morphological evaluation of biopsies, electron microscopy, and extensive immunohistochemical studies. Immunohistochemical studies showed that the neoplastic cells expressed the gamma/delta T-cell receptor (CD3+, C gamma M1+) and were CD2+, CD43+, CD45+, CD45RO+, PCNA+, but were beta F1-, CD1-, CD4-, CD8-, CD15-, CD20-, CD25-, CD30-, CD45R-, CD57-, CD68-, Mac 387-, and HLA Dr-. To the best of our knowledge, this is the first report of a subcutaneous T-cell lymphoma of gamma/delta type involving the subcutaneous tissue and associated with a hemophagocytic syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7978074     DOI: 10.1097/00000372-199408000-00014

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  2 in total

1.  Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes.

Authors:  G K Przybylski; H Wu; W R Macon; J Finan; D G Leonard; R E Felgar; J A DiGiuseppe; P C Nowell; S H Swerdlow; M E Kadin; M A Wasik; K E Salhany
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  Primary cutaneous γ/δ T-cell lymphoma. An atypical case with bone marrow granulomas.

Authors:  Guy Shalom; Ronit Gurion; Daniel Benharroch
Journal:  J Dermatol Case Rep       Date:  2015-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.